ProEthic Pharmaceuticals Announces U.S. Availability Of Lipofen
Montgomery, AL - ProEthic Pharmaceuticals, Inc. recently announced that Lipofen (fenofibrate capsules), a new prescription treatment for cholesterol disorders, is now available in U.S. pharmacies. Lipofen is indicated as adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides (TG), and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Lipofen is also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia).
Lipofen is a new formulation containing the active ingredient fenofibrate, which utilizes patented Lidose Technology to enhance the absorption of fenofibrate. Lipofen can help patients manage elevated triglycerides and their entire cholesterol profile when diet alone is not sufficient. Lipofen is available in 150 mg and 50 mg capsules.
Carl Whatley, Chairman and CEO of ProEthic Pharmaceuticals, stated, "We are pleased to offer a new and efficacious treatment option to patients seeking to reach their lipid goals. Lipofen has been clinically proven to provide significant triglyceride reductions and may also reduce "bad" cholesterol by up to 31% while increasing "good" cholesterol by up to 15%."
Mr. Whatley continued, "The use of fenofibrates has escalated rapidly in recent years, with increased patient demand expected to continue. Lipofen will provide ProEthic with an important commercial opportunity in this market, while at the same time, strengthening our presence in the primary care space as we continue to advance our valuable clinical treatment programs in migraine and acute pain. We believe that the establishment of Lipofen as the lead product in our company's portfolio will enable us to continue our strong record of growth as well as help to build significant shareholder value."
In July 2007, ProEthic announced that it had acquired the exclusive ten year marketing, sales and distribution rights to Lipofen in the U.S., its territories and possessions from Cipher Pharmaceuticals, Inc.
SOURCE: ProEthic Pharmaceuticals, Inc.